A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer's Disease Mice Models.
A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer's Disease Mice Models.
复制标题
DOI：
10.3390/ph15080908
复制
发表时间：
2022-07-22
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
Alzheimer’s disease (AD) is a progressive neurological disorder with multifactorial and heterogeneous causes. AD involves several etiopathogenic mechanisms such as aberrant protein accumulation, neurotransmitter deficits, synaptic dysfunction and neuroinflammation, which lead to cognitive decline. Unfortunately, the currently available anti-AD drugs only alleviate the symptoms temporarily and provide a limited therapeutic effect. Thus, new therapeutic strategies, including multitarget approaches, are urgently needed. It has been demonstrated that a co-treatment of acetylcholinesterase (AChE) inhibitor with other neuroprotective agents has beneficial effects on cognition. Here, we have assessed the neuroprotective effects of chronic dual treatment with a soluble epoxide hydrolase (sEH) inhibitor (TPPU) and an AChE inhibitor (6-chlorotacrine or rivastigmine) in in vivo studies. Interestingly, we have found beneficial effects after chronic low-dose co-treatment with TPPU and 6-chlorotacrine in the senescence-accelerated mouse prone 8 (SAMP8) mouse model as well as with TPPU and rivastigmine co-treatment in the 5XFAD mouse model, in comparison with the corresponding monotherapy treatments. In the SAMP8 model, no substantial improvements in synaptic plasticity markers were found, but the co-treatment of TPPU and 6-chlorotacrine led to a significantly reduced gene expression of neuroinflammatory markers, such as interleukin 6 (Il-6), triggering receptor expressed on myeloid cell 2 (Trem2) and glial fibrillary acidic protein (Gfap). In 5XFAD mice, chronic low-dose co-treatment of TPPU and rivastigmine led to enhanced protein levels of synaptic plasticity markers, such as the phospho-cAMP response element-binding protein (p-CREB) ratio, brain-derived neurotrophic factor (BDNF) and postsynaptic density protein 95 (PSD95), and also to a reduction in neuroinflammatory gene expression. Collectively, these results support the neuroprotectant role of chronic low-dose co-treatment strategy with sEH and AChE inhibitors in AD mouse models, opening new avenues for effective AD treatment.
登录
查看更多内容
DOI：
10.1016/j.jalz.2010.04.006
发表时间：
2010-09
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Iqbal K;Grundke-Iqbal I
通讯作者：
Grundke-Iqbal I
Akt/CREB 信号通路参与 EPA 对白细胞介素 1β 诱导的细胞毒性和培养的大鼠海马神经元 BDNF 下调的保护作用
影响因子：
2.4
作者：
Dong Y;Pu K;Duan W;Chen H;Chen L;Wang Y
通讯作者：
Wang Y
影响因子：
7.3
作者：
Codony S;Pont C;Griñán-Ferré C;Di Pede-Mattatelli A;Calvó-Tusell C;Feixas F;Osuna S;Jarné-Ferrer J;Naldi M;Bartolini M;Loza MI;Brea J;Pérez B;Bartra C;Sanfeliu C;Juárez-Jiménez J;Morisseau C;Hammock BD;Pallàs M;Vázquez S;Muñoz-Torrero D
通讯作者：
Muñoz-Torrero D
DOI：
10.1016/j.bbih.2021.100325
发表时间：
2021-10
期刊：
Brain, behavior, & immunity - health
影响因子：
--
作者：
Borsini A
通讯作者：
Borsini A
DOI：
10.1002/trc2.12050
发表时间：
2020-01-01
影响因子：
4.8
作者：
Cummings, Jeffrey;Lee, Garam;Zhong, Kate
通讯作者：
Zhong, Kate